AD: Breakthrough in Alzheimer’s Could Transform Lives!

Company Overview

Alaris Equity Partners Income Trust (Ticker: AD.UN) – despite the Alzheimer’s-themed title – is a Calgary-based alternative financing company, not a biotech firm. “AD” here refers to Alaris’s stock symbol on the Toronto Stock Exchange. Alaris provides growth capital to well-run, profitable private businesses in exchange for regular preferred equity distributions (^[1]). These partner companies span various industries (e.g. business services, healthcare services, industrial) and are often family-owned firms seeking funding for expansion, buyouts, or succession planning (^[1]). Alaris structures investments as perpetual preferred equity (and sometimes minority common equity) yielding typically ~12–15% annually. The cash distributions from partners are contractually set about a year in advance and then adjusted annually based on each partner’s revenue growth or other top-line metrics (with collars to limit swings) (^[1]). This model lets Alaris earn steady cash flows that grow organically ~3–5% per year as partners’ businesses expand (^[1]). In essence, Alaris is an income-generating fund that helps private companies grow while delivering high-yield distributions to its own unitholders.

The title’s reference to an Alzheimer's breakthrough underscores how transformative developments can improve lives. In Alaris’s case, the “breakthroughs” are financial – enabling small businesses to flourish without giving up control. While not directly involved in medical innovation, Alaris aims to create positive impacts by fostering stable growth in its portfolio companies.

Dividend Policy & History

Alaris has a strong yield-focused dividend policy, with a current yield around 7–8%. The trust’s mandate is to pay “stable, predictable and growing” cash distributions on a tax-efficient basis (^[1]). Historically, Alaris paid monthly dividends, but in March 2020 it switched to quarterly payouts – a move coinciding with pandemic disruptions. The first quarterly distribution was set at $0.31 per unit (paid July 15, 2020) (^[1]). This effectively reduced the annualized dividend to ~$1.24, reflecting a cautious stance amid COVID-19 stresses on some partners. As conditions improved, Alaris resumed dividend growth: in Q3 2021 it raised the payout 6.5% to $1.32 annualized ($0.33 quarterly) (^[1]). The next year, in late 2022, it announced a further 3% increase to $1.36 ($0.34 quarterly) (^[1]). Most recently, on the back of strong performance and a low payout ratio, the Board approved a 9% hike in Q4 2025 to $1.48 annualized (now $0.37 per quarter) (^[2]). This trend of gradual increases underscores management’s confidence in cash flow growth.

URGENT: Get “Trump\'s Secret Fund” — Learn How to Collect Royalty Checks

Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.

Mobile-friendly
Start w/ $50

Yes — Send My Report
Fast download • Instant access • Seats limited

At a share price around C$20, the stock yields roughly 7.0–7.5% after the latest raise (for context, it was ~6.5% before the increase at a C$21 price) (^[3]) (^[3]). Dividends are well-supported by underlying cash flows (discussed below) and have room for growth. Notably, Alaris chose to cut and restructure its dividend in 2020 amid the pandemic, highlighting management’s willingness to adjust payouts to preserve the balance sheet (^[1]). Since then, restoration of full partner payments allowed Alaris to steadily boost distributions again. The trust’s clear objective is to grow the payout over time, funded by new investments and organic increases from existing partners.

Cash Flows and Coverage (AFFO/FFO)

Alaris’s distribution coverage is robust, thanks to its high-margin cash streams from partners. Traditional REIT metrics like FFO/AFFO are not directly reported, but Alaris discloses its payout ratio relative to operating cash flow. In 2023, the trust’s “Actual Payout Ratio” was about 64% (after adjusting for one-time legal costs) (^[4]). This means only about two-thirds of cash earnings were paid out as distributions – a healthy coverage buffer. In practical terms, Alaris generated roughly C$2.10–$2.20 of cash per unit in 2023 against the $1.36 per unit distributed, leaving significant retained cash. Management expects the forward payout ratio to remain in a conservative 65–70% range even after the recent dividend increase (^[2]) (^[2]). This implies ongoing cash flow comfortably exceeds the dividend.

Underlying this safety is the strength of Alaris’s partners. As of year-end 2023, the weighted-average Earnings Coverage Ratio (ECR) at the partner level was >1.5×, meaning on average the portfolio companies earned 1.5 times the amount needed to cover their payments to Alaris (^[4]). In fact, 11 of 20 partners had ECR above 1.5×, and 75% of partners had ECR >1.2× (^[5]). Many partners also carry little debt (12 of 20 had <1.0× Debt/EBITDA) (^[4]), which adds resilience (^[4]). This all translates into reliable distribution income for Alaris. Even during 2020’s downturn, most partner payouts eventually resumed (deferred amounts were later caught up) (^[6]) (^[5]). Alaris’s practice of diversifying across ~20 partners (with no single investment contributing more than ~12% of revenue) also protects its cash flows (^[6]). Overall, the dividend is well-covered by recurring cash flows, and the trust retains a cushion of free cash (or “retained AFFO”) for reinvestment, debt repayment, or future distribution hikes.

Leverage and Debt Maturities

Alaris employs moderate leverage to enhance returns, but it maintains a prudent debt profile with no near-term maturity cliffs. The trust primarily funds deals using a C$500 million revolving credit facility, alongside periodic bond offerings. As of Dec 31, 2023, Alaris had drawn ~C$242 million on its revolver (net of fees) (^[4]) – roughly half the available capacity. The facility was recently upsized from $450M to $500M and had its pricing improved (^[4]) (^[4]). Alaris’s interest cost on the credit line averaged ~7.9% in 2023 amid higher base rates (^[4]). Notably, lenders agreed to loosen the senior debt covenant from 2.5× to 3.0× debt/EBITDA, reflecting comfort with Alaris’s stable cash flows (^[4]). Current net debt-to-EBITDA is around 1.5–2.0× (depending on whether one includes non-cash gains), indicating ample headroom.

MARKET ALERT

GOLD +31% YTD
SILVER +14% YTD
THM +5090% (historic example)
Copper Lake +13,025% (1970s)
Sean’s 5 Gold Picks — Free

Get The Reports

In addition to bank debt, Alaris has issued unsecured debentures to term out its leverage at fixed rates. In early 2022, it sold C$65 million of 5-year debentures due March 31, 2027 at a 6.25% coupon (^[7]) (^[7]). These notes are redeemable starting in 2025 and can be repaid in cash or, at maturity, in units at Alaris’s option (^[7]) (^[7]). More recently, in mid-2025 Alaris raised C$75 million (plus an overallotment) of convertible unsecured debentures due June 2030 with a 6.5% coupon (^[8]). Investors have the option to convert these 2030 debentures into trust units (the conversion price was set at a premium) (^[8]). The proceeds from these debt issuances have been used mainly to pay down revolver borrowings and fund new investments (^[8]), effectively locking in lower fixed rates and providing liquidity for growth.

Alaris’s debt maturity schedule is well-laddered: the next maturity is the 2027 debenture (C$65M), followed by the 2030 convertible issue, while the credit facility is typically extended or refinanced periodically (no indication of near-term expiry, and capacity remains). With a market cap near C$950 million and book equity of ~$21 per unit (C$900+ million total) (^[4]) (^[3]), the trust’s leverage is reasonable (roughly 30–35% debt-to-total capitalization). Interest coverage is strong – EBITDA far exceeds interest obligations. In 2023, interest plus taxes were C$56.1M (^[4]), while EBITDA (including some gains) was C$202M (^[4]); even on a cash basis, coverage is several times. Overall, Alaris has managed its balance sheet conservatively: borrowings are modest relative to cash flow, and recent fundraising (debt and some equity issuance) provides liquidity to seize new investment opportunities without straining the balance sheet.

Valuation and Performance Metrics

At the current trading price (circa C$20 per unit), Alaris appears modestly valued relative to fundamentals. The stock trades at roughly 9×–10× normalized cash flow (P/AFFO) and around 0.9× book value. For instance, year-end 2023 book value was C$21.12 per unit – a record high (^[4]) – and units recently trade just below that level, implying a slight discount to the fair value of net assets. Traditional earnings multiples are deceptively low: the trailing P/E ratio is ~6 (^[3]), but reported IFRS earnings include volatile unrealized gains/losses on investments. More meaningful is the cash yield: the forward dividend yield of ~7.0% is quite attractive, especially given the 60–70% payout ratio (indicating a ~11–12% cash earnings yield). By comparison, many income-focused securities (REITs, BDCs) trade at higher multiples or similar yields with higher payout ratios. Alaris’s ~7–8% yield, underpinned by relatively low leverage and diversified private assets, suggests the market is pricing in a degree of caution (likely due to its small-cap size and unique model).

Meet the 3 Pillars of Dollar 2.0

Tap to flip the card for names, tickers, and a quick playbook.

Fast-read
2 min

Three Stocks to Watch

Mint Co. — Payment rails + 4.1% yields
Platform Leader — Exchange & custody powerhouse
Infrastructure Giant — Backbone tech, fees on every transaction

Show Me Tickers & Strategy

Analysts generally have a favorable view. The consensus price target is around C$24 (^[3]), about 15–20% above current levels, and the stock is rated a “Moderate Buy.” This reflects expectations that Alaris can continue deploying capital at high returns and steadily grow its distributions. In terms of peer comparison, few public companies have an identical model. In Canada, one could compare to other alternative lenders or royalty companies (e.g. Diversified Royalty Corp or various private equity-like income funds). Many of those yield ~6–8% as well, though Alaris distinguishes itself with its long track record (since 2008) and a portfolio that has weathered economic cycles. It’s worth noting that Alaris’s unit price, like many financial stocks, can be sensitive to interest rates and economic sentiment. The stock is up about +6.6% YTD (^[9]) in 2025, reflecting improved results, but it still trades below pre-pandemic highs (mid-$20s). The valuation thus appears reasonable to undervalued if one trusts the stability of its cash flows.

Key Risks and Red Flags

Despite its attractive yield, Alaris faces several risks that investors should monitor:

– Partner Performance and Concentration: Alaris’s revenue depends entirely on its private partners honoring their distribution obligations. If a partner’s business deteriorates, they may reduce or suspend payments. This occurred during COVID-19 – e.g. several partners in fitness and hospitality deferred distributions in 2020, forcing Alaris to temporarily reduce its own payout (^[1]). While diversification has improved (no single partner is more than ~12% of revenue (^[6])), the portfolio is only ~20 companies – a few large setbacks could meaningfully hit cash flow. Close attention to partner financial health (coverage ratios, debt loads) is critical. So far, Alaris’s due diligence has been strong – most partners remained resilient through 2020 with the average coverage actually improving to 1.7× by end of 2020 (^[6]) (^[6]). Still, idiosyncratic risks exist: for example, if a partner loses a key customer or faces fraud, Alaris’s income could drop and possibly force a distribution cut.

– Legal and Structuring Risks: Alaris’s preferred equity deals sometimes lead to disputes or complexity. A red flag was the recent litigation with Sandbox Advertising, a former partner – a dispute that incurred legal costs and was settled in 2023 (^[4]). While the issue was resolved (and legal expenses have subsided), it shows that enforcement of Alaris’s agreements isn’t always smooth. Additionally, many partners have buyout (“redemption”) options after a few years. If a partner redeems Alaris’s investment early (often at a premium formula), Alaris must redeploy that capital. Redemption can be a double-edged sword: it realizes gains for Alaris but cuts off a productive income stream, and finding a replacement investment can take time. A wave of redemptions in a hot market could temporarily reduce Alaris’s cash flow if new deals aren’t immediately available.

– Interest Rate and Funding Risk: As a yield vehicle, Alaris is sensitive to interest rates. Rising rates raise the cost of Alaris’s debt (its floating-rate loan interest hit ~7.9% in 2023) (^[4]), which compresses its net interest margin. Higher interest benchmarks also mean investors demand higher yields, putting downward pressure on income-stock valuations (Alaris’s yield may need to stay elevated to remain attractive). Conversely, if rates fall, some partners might find cheaper capital elsewhere and redeem Alaris’s stake. Alaris mitigates rate risk by fixing a portion of its debt at ~6.25–6.5% and maintaining a low payout (cushion for interest expense), but persistent high rates could slow its growth (fewer accretive deals) or crimp coverage if borrowing costs climb further. Additionally, Alaris occasionally issues equity (e.g. equity raises in 2020–21 at depressed prices (^[6])) – dilution can be a risk if the unit price drops significantly. The small trading float (~70k shares daily volume (^[3])) could itself be a risk, as liquidity is limited.

– Economic Cyclicality: Although Alaris selects partners that operate in “required services” niches (^[6]), a severe recession would test its model. Declining revenues at portfolio companies would trigger distribution resets downward (Alaris’s payouts from partners adjust with top-line metrics, sometimes with a lag). A broad slowdown could also increase the odds of partner defaults or covenant breaches. Notably, during the 2020 shutdown, Alaris’s stock price plunged (bottoming near ~$7 in March 2020) as the market feared widespread partner failures (^[6]). In reality, most partners coped and rebounded, but it demonstrated that market sentiment can swing wildly. Investors should be prepared for volatility and monitor macro indicators (consumer spending, industrial activity) that might foreshadow stress in Alaris’s diverse portfolio (which includes sectors like gyms, clinics, construction services, etc.).

– Foreign Exchange Exposure: The majority of Alaris’s investments are in the United States, meaning USD/CAD fluctuations can impact reported results. A strengthening Canadian dollar can reduce the translated value of U.S. partner distributions. Alaris does not fully hedge this exposure; management assumes USD will stay within ±15% of current levels for planning purposes (^[4]). Significant currency moves could therefore be a minor headwind or tailwind to cash flow in CAD terms.

In summary, while Alaris’s model has proven resilient, risks lurk in the underlying private investments and external environment. The trust has taken steps to mitigate these (diversification, structuring protections, low payout ratio), but investors should keep an eye on partner updates each quarter. Any sign of multiple partners underperforming is a potential red flag for future distribution stability.

Outlook and Open Questions

Looking ahead, several key questions and themes surround Alaris’s investment thesis:

– Growth Pipeline and Deployment: Alaris’s ability to continue finding attractive partner investments is crucial for growth. Management insists the deal pipeline remains strong and that many private businesses seek non-control capital (^[2]). Indeed, in late 2025 Alaris announced a major C$115.5 million investment into a new partner (Optimus SBR) (^[9]) and multiple follow-on investments. With roughly C$250+ million of dry powder (undrawn credit plus retained cash), a pertinent question is how efficiently can Alaris put this capital to work? The trust targets a high teens internal rate of return (IRR) on deals (^[2]), but competition from private equity and higher-rate debt could pressure yields. Investors will watch if deployment accelerates in 2024–2025 and whether those new investments sustain the ~14% average initial yields Alaris has historically achieved (^[2]). If Alaris cannot find enough quality partners, its growth (and ability to keep raising the dividend) could stall.

– Common Equity Upside vs. Risk: In recent years Alaris has taken common equity stakes in about 15 of its partners to participate in their upside (^[2]). This has paid off – in 2023 Alaris saw $58.2 million in unrealized gains on its common equity positions (^[4]), boosting book value. The strategy could materially enhance long-term returns (management cites a 41.8% total return on common investments in 2023) (^[4]). However, it also introduces more volatility: common equity can lose value if a partner falters. An open question is how this shift toward equity exposure will play out in a downturn. So far it’s been beneficial, but investors should evaluate whether Alaris’s risk/return profile is edging closer to a hybrid of private equity rather than a pure fixed-income-like stream. The trust’s low P/E in part reflects these unrealized gains (which might not recur every year). Monitoring the outcomes of exits (sales) of these equity stakes will be informative – e.g. successful redemptions like the Unify partnership exit in 2023 yielded a 16% IRR (^[10]), but not every deal may achieve that.

– External Impact – Could Medical Breakthroughs Matter?: Although Alaris is far removed from drug development, broad societal changes can indirectly affect it. For instance, a true breakthrough in Alzheimer’s disease treatment could transform the healthcare landscape – potentially reducing burdens on senior care facilities or increasing longevity. If such an event occurred, how might it touch Alaris? One angle: Alaris has invested in healthcare services firms (e.g. clinics, behavioral health) that could see new opportunities or lower costs if Alzheimer’s became more treatable. More generally, Alaris benefits from a growing economy; a healthier aging population might spend more on services provided by some partners. These connections are speculative, but they underscore that Alaris’s fortunes rise with the prosperity of the communities its partners serve. Any major positive “black swan” – be it technological or medical – that boosts economic activity and confidence is likely a tailwind for Alaris’s portfolio. Conversely, game-changing disruptions in how business is done (for example, if AI or telehealth drastically alter certain industries) could require Alaris to adapt its investment approach.

– Capital Management and Shareholder Returns: With the payout ratio deliberately under 70%, Alaris retains significant cash. Management has stated it will use excess cash for further distribution increases and unit buybacks when appropriate (^[2]). Indeed, a normal course issuer bid was active in 2025 (^[9]). An open question is to what extent will Alaris prioritize buybacks versus new deals or dividend hikes? If the stock stays undervalued (yield high relative to opportunity), repurchasing units could be accretive. The trust increased its dividend in 2025 and still stayed below the target payout range (^[2]), implying room for more raises. Investors can anticipate a careful balance: funding growth opportunities while returning surplus cash. Monitoring management’s capital allocation (for example, did they execute the announced buyback plan in full? (^[9])) will provide insight into their confidence in deal pipeline versus the attractiveness of their own stock.

In conclusion, Alaris Equity Partners (AD.UN) offers a compelling high-yield, income-growth story underpinned by a unique private equity income model. The company has transformed the lives of many small business owners by providing capital without forcing ownership relinquishment – a different kind of “breakthrough” that enables those entrepreneurs to scale and create jobs. For investors, Alaris delivers an ample dividend that has been growing once again, with solid coverage and thoughtful risk management. The road ahead includes navigating economic cycles and capital markets, but if Alaris can continue executing, it stands to reward unitholders with attractive total returns. Much like a medical breakthrough would be life-changing for patients, a sustained successful investment strategy here could be financially transformative for shareholders – making AD a ticker to watch in the income investing space.

Sources: Alaris Equity Partners investor releases and financial reports (^[4]) (^[2]) (^[1]) (^[4]); Market data from MarketBeat and filings (^[3]) (^[3]); Company presentations and news releases (^[1]) (^[6]).

Sources

For informational purposes only; not investment advice.